Therapeutic Action
Sirolimus has been shown to inhibit a number of key disease-related biological processes, positioning the compound as a potentially highly efficacious therapeutic for a wide range of ocular diseases and conditions.
 |
 |
Sirolimus' Known Action
| Potential Relevance to
Ocular Disease
|
Anti-angiogenesis |
Inhibits formation of new blood vessels linked to vision-impairing diseases such as AMD and diabetic retinopathy |
Anti-proliferation |
Prevents proliferation of key cells required for formation of new blood vessels in the angiogenic process that is implicated in a number of ocular diseases including wet AMD and diabetic retinopathy |
Anti-migration |
Inhibits migration of endothelial cells in response to cytokines. Cellular migration is a necessary step in the angiogenic process associated with such ocular diseases as wet AMD and proliferative diabetic retinopathy |
Anti-fibrosis |
Inhibits formation of scar tissue. Scarring results from the tissue disruption and damage associated with AMD and other ocular diseases |
Immunosuppression |
Inhibits T- and B-cell activity and down-regulates multiple pro-inflammatory factors tied to ocular diseases such as dry eye and uveitis |
Anti-permeability |
Inhibits blood vessel leakage (permeability) associated with the angiogenic process in wet AMD, diabetic retinopathy and other diseases and conditions that affect central vision |
 |
 |
|
